Paris J, Paris J C, Gérard A
Nouv Presse Med. 1981 Feb 26;10(8):647-9.
Cefotaxime was administered alone to 25 patients, with serious infectious diseases secondary to a gastrointestinal lesion. The largest group consisted of pancreatic and biliary infections, or infectious complication in cirrhotic patients. The daily dose was 2 or 3 g, sometime 4 g of cefotaxime. In the 15 cases where the infecting organisms could be identified: E. coli: 6, Staphylococcus aureus: 4, Klebsiella: 2, Haemophilus: 1, Proteus: 1 and Pseudomonas: 1, the pathogen was eradicated bacteriologically within two to six days after the onset of therapy. The infection was controlled in all 25 cases within 2 to 8 days even though, in 11 cases, previous antibiotic therapy had been insufficient, no complementary antibiotic treatment was associated and 8 of the cases with very severe infection were a serious problem to the intensive care unit. The use of cefotaxime is justified in the treatment of gastrointestinal infection even though pathogens are identified with difficulty in these diseases.
25例继发于胃肠道病变的严重感染性疾病患者单独使用头孢噻肟进行治疗。最大的一组包括胰腺和胆道感染,或肝硬化患者的感染性并发症。头孢噻肟的日剂量为2或3克,有时为4克。在15例可鉴定出感染病原体的病例中:大肠杆菌6例、金黄色葡萄球菌4例、克雷伯菌2例、嗜血杆菌1例、变形杆菌1例和假单胞菌1例,病原体在治疗开始后2至6天内从细菌学上被根除。尽管在11例病例中先前的抗生素治疗不足、未联合使用补充性抗生素治疗且8例严重感染病例对重症监护病房来说是严重问题,但所有25例病例的感染均在2至8天内得到控制。即使在这些疾病中难以鉴定出病原体,头孢噻肟在胃肠道感染的治疗中也是合理的。